Antidepressant medications were originally approved by the FDA based on 8-to-12-week clinical studies despite widespread long-term usage.

Overview Debates Related claims Topics Sources

In England, estimated financial costs from adverse childhood experiences were £37.8 billion for mental illness and £22.7 billion for smoking, while in Wales each accounted for £1.8 billion.

The American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptoms

The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.

Treatment-resistant depression is estimated to affect approximately 4 million people in the U.S., with fewer than 5% receiving a treatment indicated for the condition.

A survey commissioned by Compass Pathways revealed that nearly two in three caregivers report treatment-resistant depression impacts family health, with over half experiencing a major toll on their own mental health.

A survey commissioned by Compass Pathways found that nearly 95% of individuals living with treatment-resistant depression describe themselves as functioning but struggling, surviving day-to-day, or barely getting by.

Canada should exclude mental illness as a sole condition for medically assisted dying

Outro plans to use its $7 million in capital to expand its network of deprescribing clinicians and develop artificial intelligence clinical decision support tools.

Approximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.

Outro's deprescribing platform incorporates personalized hyperbolic tapering plans, compounded medication doses, patient monitoring, and specially-trained clinicians.

Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.

Research led by Dr. Mark Horowitz found that four in five long-term antidepressant users were unable to stop taking their medications due to withdrawal symptoms.

Hyperbolic tapering is the most effective protocol for discontinuing psychiatric medications

Commercial digital platforms are suitable for managing complex psychiatric drug withdrawal

U.S. healthcare providers should prioritize deprescribing over long-term psychiatric medication maintenance

FDA approval standards based on short-term trials adequately protect long-term antidepressant users

Victoria should launch targeted public health campaigns on cannabis risks for young women

Cannabis-related admissions create an unsustainable strain on Victoria's public health system

Cannabis consumption poses a severe public health risk through induced psychosis